SALT LAKE CITY, November 19, 2024 /PRNewswire/ — Utah-based Second Heart Assist Inc., announced continued successes in additional clinical studies in South America. Through a series of planned studies, Second Heart Assist has yet again demonstrated significant safety and efficacy in OUS trials for its Whisper™ device, uniquely poised to tackle multiple indications of HF including HR-PCI, ADHF, and CS non-invasively. This device can be deployed in under 2 min and has the potential to be the safest, fastest, and easiest to use device to enter the market with the highest perfusion / lowest hemolysis on the market horizon.
